Aclaris Therapeutics, Inc.
ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Conā¦ read more
Healthcare
Diagnostics & Research
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.32
Price+2.20%
$0.05
1Y
Price
Market Cap
$251.355m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-856.2%
EBITDA Margin-868.3%
Net Profit Margin-563.5%
Free Cash Flow MarginRevenue
$16.789m
-10.3%
1y CAGR-15.1%
3y CAGR+73.7%
5y CAGREarnings
-$134.652m
-2.0%
1y CAGR-17.7%
3y CAGR-12.2%
5y CAGREPS
-$1.37
+19.9%
1y CAGR-3.4%
3y CAGR+1.7%
5y CAGRBook Value
$131.739m
$189.147m
Assets$57.408m
Liabilities$2.366m
DebtDebt to Assets
1.3%
-
Debt to EBITDAFree Cash Flow
-$45.862m
-127.1%
1y CAGR-23.1%
3y CAGR-24.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company